DC-SIGN Antibody (MR-1): sc-59157

DC-SIGN Antibody (MR-1) is a mouse monoclonal IgG1 antibody raised against human DC-SIGN (CD209), a crucial type II membrane protein central to immune system function. Anti-DC-SIGN antibody (MR-1) recognizes an epitope within the DC-SIGN immunogen sequence and demonstrates specificity for human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. DC-SIGN exhibits sophisticated organization and function through its unique C-type lectin domain structure. This specialized domain enables DC-SIGN to recognize and bind various pathogens, most notably HIV-1, with remarkable specificity. DC-SIGN maintains precise expression patterns, appearing predominantly on dendritic cells - the professional antigen-presenting cells of the immune system that bridge innate and adaptive immunity by presenting antigens to T cells. The interaction between DC-SIGN and pathogens proves particularly significant in HIV-1 infection, where DC-SIGN not only facilitates initial pathogen capture but also enhances viral transmission to T cells, influencing disease progression. Through these diverse immunological functions, DC-SIGN (MR-1) antibody provides researchers with a valuable tool for investigating both normal dendritic cell function and viral immune evasion mechanisms in immunology and virology research.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DC-SIGN Antibody (MR-1) References:

1. Cyclic nucleotides promote monocyte differentiation toward a DC-SIGN+ (CD209) intermediate cell and impair differentiation into dendritic cells.  |  Giordano, D., et al. 2003. J Immunol. 171: 6421-30. PMID: 14662841
2. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas.  |  Cheong, C., et al. 2010. Cell. 143: 416-29. PMID: 21029863
3. Role of DC-SIGN and L-SIGN receptors in HIV-1 vertical transmission.  |  da Silva, RC., et al. 2011. Hum Immunol. 72: 305-11. PMID: 21277928
4. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.  |  van Kooyk, Y., et al. 2013. Mol Immunol. 55: 143-5. PMID: 23158834
5. Association of Oligoadenylate Synthetase Gene Cluster and DC-SIGN (CD209) Gene Polymorphisms with Clinical Symptoms in Chikungunya Virus Infection.  |  Chaaithanya, IK., et al. 2016. DNA Cell Biol. 35: 44-50. PMID: 26398832
6. Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or DC-SIGN.  |  Gao, H., et al. 2020. Carbohydr Res. 487: 107877. PMID: 31766009
7. CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration, and Therapeutic Targeting.  |  Marzaioli, V., et al. 2021. Front Immunol. 12: 722349. PMID: 35095831
8. CSF-1-induced DC-SIGN+ macrophages are present in the ovarian endometriosis.  |  Xiaocui, L., et al. 2022. Reprod Biol Endocrinol. 20: 48. PMID: 35260161
9. Mannobioside biomimetics that trigger DC-SIGN binding selectivity.  |  Herrera-González, I., et al. 2022. Chem Commun (Camb). 58: 12086-12089. PMID: 36219150
10. CD209 signaling pathway as a biomarker for cisplatin chemotherapy response in small cell lung cancer.  |  Lin, A., et al. 2024. Genes Dis. 11: 101038. PMID: 38274378

The preferred DC-SIGN antibody is DC-SIGN Antibody (DC28): sc-65740.